{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:51:19Z","timestamp":1777711879071,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajo.2024.12.023","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T11:37:49Z","timestamp":1735645069000},"page":"466-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparison of Renal Adverse Events Between Intravitreal Anti\u2013Vascular Endothelial Growth Factor Agents: A Meta-Analysis"],"prefix":"10.1016","volume":"271","author":[{"given":"Ryan S.","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Balas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaditeya","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-6472","authenticated-orcid":false,"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2024.12.023_bib0001","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.oret.2021.12.019","article-title":"Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis","volume":"6","author":"Reibaldi","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2024.12.023_bib0002","doi-asserted-by":"crossref","first-page":"xli","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of intravitreal therapy for retinal diseases\u2014from CMV to CNV: the LXXIV Edward Jackson Memorial Lecture","volume":"191","author":"Martin","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.023_bib0003","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41433-021-01646-3","article-title":"Intravitreal injections: past trends and future projections within a UK tertiary hospital","volume":"36","author":"Chopra","year":"2022","journal-title":"Eye"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.023_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35148","article-title":"Intravitreal vascular endothelial growth factor inhibitor therapy in Denmark and 5-year projections","volume":"6","author":"Thinggaard","year":"2023","journal-title":"JAMA Network Open"},{"issue":"10 suppl","key":"10.1016\/j.ajo.2024.12.023_bib0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.023_bib0006","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.survophthal.2016.03.010","article-title":"Vascular endothelial growth factor and diabetic macular edema","volume":"61","author":"Lally","year":"2016","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.023_bib0007","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1573399811666150615151324","article-title":"Anti-VEGF therapy for retinal vein occlusions","volume":"17","author":"Campa","year":"2016","journal-title":"Curr Drug Targets"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.023_bib0008","first-page":"85","article-title":"Acute kidney injury: definition, pathophysiology and clinical phenotypes","volume":"37","author":"Makris","year":"2016","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.023_bib0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.023_bib0010","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.023_bib0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3904\/kjim.2003.18.2.65","article-title":"Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease","volume":"18","author":"Kim","year":"2003","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.ajo.2024.12.023_bib0012","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-physiol-021115-105412","article-title":"Vascular growth factors and glomerular disease","volume":"78","author":"Bartlett","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.023_bib0013","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.023_bib0014","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40259-023-00621-6","article-title":"Acute kidney injury from intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Tsao","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.ajo.2024.12.023_bib0015","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.023_bib0016","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.023_bib0017","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.023_bib0018","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.023_bib0019","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.023_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.023_bib0021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL Study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.023_bib0022","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.023_bib0023","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jama.2022.25029","article-title":"Four-year visual outcomes in the protocol w randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy","volume":"329","author":"Maturi","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.023_bib0024","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"10326","key":"10.1016\/j.ajo.2024.12.023_bib0025","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.023_bib0026","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.023_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.023_bib0028","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors","volume":"57","author":"Pell\u00e9","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.023_bib0029","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ckj\/sfab066","article-title":"Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration","volume":"14","author":"Phadke","year":"2021","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.023_bib0030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","article-title":"Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy","volume":"13","author":"Shye","year":"2020","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.023_bib0031","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nefro.2016.10.011","article-title":"Renal damage associated to intravitreal administration of ranibizumab","volume":"37","author":"Morales","year":"2017","journal-title":"Nefrologia"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.023_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100326","article-title":"The association of intravitreal anti-VEGF injections with kidney function in diabetic retinopathy","volume":"3","author":"Bunge","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.023_bib0033","article-title":"Changes of estimated glomerular filtration rate and glycated hemoglobin A1c in diabetic macular edema patients treated by ranibizumab and aflibercept in the tertiary referral hospital","volume":"58","author":"Ku","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.023_bib0034","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.oret.2024.03.014","article-title":"Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an Observational Health Data Sciences and Informatics Network Study","volume":"8","author":"Cai","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.023_bib0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.023_bib0036","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2024.01.016","article-title":"Systemic arterial and venous thrombotic events associated with anti-vascular endothelial growth factor injections: a meta-analysis","volume":"262","author":"Jhaveri","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.023_bib0037","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.ophtha.2024.06.011","article-title":"International classification system for ocular complications of anti-VEGF agents in clinical trials","volume":"131","author":"Popovic","year":"2024","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.023_bib0038","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.023_bib0039","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ophtha.2018.01.019","article-title":"Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"125","author":"Jampol","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.023_bib0040","article-title":"Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab","volume":"8","author":"Hanna","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.023_bib0041","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.023_bib0042","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.4103\/1735-1995.172845","article-title":"Diabetes mellitus and renal failure: prevention and management","volume":"20","author":"Nasri","year":"2015","journal-title":"J Res Med Sci"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.023_bib0043","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ajo.2024.12.023_bib0044","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2045-3701-4-27","article-title":"Diabetic macular edema: new concepts in patho-physiology and treatment","volume":"4","author":"Zhang","year":"2014","journal-title":"Cell Biosci"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.023_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","article-title":"Vascular complications of diabetes: mechanisms of injury and protective factors","volume":"17","author":"Rask-Madsen","year":"2013","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.023_bib0046","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.9.4.4","article-title":"Effect of a single intravitreal bevacizumab injection on proteinuria in patients with diabetes","volume":"9","author":"Chung","year":"2020","journal-title":"Transl Vis Sci Technol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:03:24Z","timestamp":1764839004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424005907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":46,"alternative-id":["S0002939424005907"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.023","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Renal Adverse Events Between Intravitreal Anti\u2013Vascular Endothelial Growth Factor Agents: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}